ELO2 Antibody

What is ELOVL2 and why is it significant in research applications?

ELOVL2 (elongation of very long chain fatty acids-like 2), also known as SSC2, elongation of very long chain fatty acids protein 2, or 3-keto acyl-CoA synthase ELOVL2, is a critical enzyme in the biosynthesis pathway of long-chain polyunsaturated fatty acids. This protein is approximately 34.6 kilodaltons in mass and consists of 296 amino acids . ELOVL2 specifically catalyzes the rate-limiting step in the elongation of C20 and C22 polyunsaturated fatty acids (PUFAs), which are essential components of cell membranes and precursors for signaling molecules.

The significance of ELOVL2 in research extends across multiple disciplines including lipid metabolism, neurodevelopment, vision science, and aging studies. Its expression is particularly notable in the liver, testes, and retina, reflecting its tissue-specific roles. Research interest has intensified as ELOVL2 has been identified as one of the most reliable epigenetic markers of aging, with its promoter methylation strongly correlating with chronological age across diverse tissues .

How can I determine which ELOVL2 antibody is appropriate for my specific research?

Selecting the appropriate ELOVL2 antibody requires careful consideration of several factors based on your experimental requirements. First, determine which applications you need the antibody for, as different antibodies are optimized for specific techniques. Based on the search results, commercially available ELOVL2 antibodies are validated for various applications including Western Blot (WB), Immunohistochemistry (IHC), Enzyme-Linked Immunosorbent Assay (ELISA), Flow Cytometry (FCM), and Immunoprecipitation (IP) .

Species reactivity is another crucial consideration. The search results indicate that many ELOVL2 antibodies demonstrate reactivity with human, mouse, and rat samples . If your research involves other species, you may need to perform preliminary validation experiments or seek antibodies specifically validated for your species of interest.

Additionally, consider the antibody format (polyclonal versus monoclonal), the specific epitope recognized, and whether conjugation to reporter molecules is required. For quantitative studies or when distinguishing between closely related proteins is essential, monoclonal antibodies may be preferable due to their higher specificity. For exploratory work or applications requiring high sensitivity, polyclonal antibodies like the rabbit polyclonal antibody (20308-1-AP) mentioned in the search results might be more suitable .

What are the optimal protocols for using ELOVL2 antibodies in immunohistochemistry?

For immunohistochemistry applications with ELOVL2 antibodies, proper antigen retrieval is critical for obtaining specific and robust staining. According to the search results, the recommended protocol for the 20308-1-AP ELOVL2 antibody includes antigen retrieval with TE buffer at pH 9.0, though citrate buffer at pH 6.0 can serve as an alternative . This step is particularly important as ELOVL2 is a membrane-associated protein that may require more rigorous retrieval conditions to expose epitopes after formalin fixation.

For detection systems, both chromogenic (DAB-based) and fluorescent secondary antibodies can be employed depending on your research needs. When high sensitivity is required, consider using amplification systems such as tyramide signal amplification, particularly for tissues with lower ELOVL2 expression levels. To minimize non-specific binding, implement thorough blocking steps using serum from the same species as your secondary antibody, and consider adding protein blockers if background staining persists.

How should I troubleshoot weak or inconsistent signals when using ELOVL2 antibodies in Western blotting?

When encountering weak or inconsistent signals in Western blotting with ELOVL2 antibodies, a systematic troubleshooting approach is essential. First, review your protein extraction method, as ELOVL2 is an integral membrane protein primarily located in the endoplasmic reticulum. Standard RIPA buffer may be insufficient for complete extraction; consider using stronger lysis buffers containing higher detergent concentrations or specialized membrane protein extraction kits.

Sample preparation is another critical factor. As a membrane protein, ELOVL2 can form aggregates when boiled in sample buffer. Instead of the standard 95°C denaturation, try heating samples at 70°C for 10 minutes. Additionally, ensure complete reduction of disulfide bonds by using fresh reducing agents in your sample buffer. The expected molecular weight for ELOVL2 is approximately 35 kDa , but post-translational modifications may result in slight variations.

For primary antibody incubation, extending the incubation time to overnight at 4°C often improves signal strength with ELOVL2 antibodies. If signal remains weak, consider increasing protein loading (40-50 μg per lane), reducing antibody dilution, or implementing signal enhancement systems. When optimizing transfer conditions, PVDF membranes are generally preferred over nitrocellulose for hydrophobic membrane proteins like ELOVL2.

Finally, include appropriate positive controls in your experiments. Based on ELOVL2's known expression pattern, liver tissue lysates or HepG2 cell extracts can serve as reliable positive controls for Western blotting applications.

What controls are essential when validating ELOVL2 antibody specificity for research applications?

Rigorous validation of antibody specificity is paramount for generating reliable research data. For ELOVL2 antibodies, implement a multi-tiered validation strategy incorporating several complementary approaches. First, include positive and negative tissue controls based on known expression patterns. Human testis and liver samples serve as excellent positive controls, as indicated in the search results , while tissues with minimal ELOVL2 expression can function as negative controls.

Western blot analysis should demonstrate a single predominant band at the expected molecular weight of approximately 35 kDa . Multiple bands may indicate non-specific binding, antibody degradation, or post-translational modifications. When available, lysates from ELOVL2 knockout or knockdown models provide compelling specificity controls. Additionally, peptide competition assays, where the antibody is pre-incubated with the immunizing peptide, can confirm binding specificity.

For immunohistochemical applications, technical controls are essential. These include primary antibody omission controls (to assess secondary antibody specificity), isotype controls (using non-specific IgG of the same species and concentration), and absorption controls. Compare staining patterns across multiple ELOVL2 antibodies targeting different epitopes when possible, as congruent patterns increase confidence in specificity.

Orthogonal validation approaches, where protein expression is correlated with mRNA levels measured by qPCR or in situ hybridization, provide additional evidence of antibody specificity. This comprehensive validation strategy ensures that observed signals genuinely represent ELOVL2 rather than cross-reactive proteins or artifacts.

How can ELOVL2 antibodies be effectively utilized in studying lipid metabolism disorders?

ELOVL2 antibodies offer valuable tools for investigating lipid metabolism disorders, particularly those involving polyunsaturated fatty acid synthesis. A strategic research approach begins with comparative expression analysis across normal and pathological tissues. Using Western blotting or quantitative immunohistochemistry, researchers can assess whether ELOVL2 expression is altered in conditions such as non-alcoholic fatty liver disease, metabolic syndrome, or specific lipid storage disorders.

For mechanistic studies, ELOVL2 antibodies can be employed in co-immunoprecipitation experiments to identify interaction partners that may be dysregulated in disease states. Combined with proteomics approaches, this can reveal novel regulatory mechanisms or pathological protein-protein interactions. Subcellular localization studies using confocal microscopy with ELOVL2 antibodies can determine whether trafficking or localization defects contribute to pathology, particularly important since ELOVL2 functions in the endoplasmic reticulum.

In experimental models where ELOVL2 expression is genetically or pharmacologically manipulated, antibodies provide essential tools for confirming intervention efficacy and correlating expression changes with functional outcomes. Tissue-specific effects can be assessed through IHC analysis across multiple organs, important because ELOVL2 functions differently in various tissues such as liver, retina, and testis . Finally, in translational research, ELOVL2 antibodies can help validate findings from animal models in human patient samples, potentially identifying novel biomarkers or therapeutic targets for lipid metabolism disorders.

What methodological approaches should be used when employing ELOVL2 antibodies in multiplex immunofluorescence studies?

Multiplex immunofluorescence with ELOVL2 antibodies requires careful methodological consideration to achieve reliable results. Begin by validating the ELOVL2 antibody in single-color immunofluorescence to confirm its performance under fluorescence detection conditions. When designing multiplex panels, select antibodies raised in different host species to avoid cross-reactivity issues. If this is not possible, sequential staining with intermediate blocking steps or directly conjugated antibodies can circumvent cross-reactivity problems.

Antigen retrieval optimization is particularly important in multiplex studies. Since ELOVL2 antibodies may require specific retrieval conditions (TE buffer pH 9.0 is recommended ), ensure that these conditions are compatible with other antibodies in your panel. When differences exist, compromise conditions or sequential staining protocols may be necessary. For optimal signal separation, select fluorophores with minimal spectral overlap and include appropriate controls for autofluorescence and spectral bleed-through.

When analyzing subcellular localization, high-resolution confocal microscopy is recommended since ELOVL2 localizes to the endoplasmic reticulum. Z-stack imaging can provide three-dimensional information about co-localization with other proteins of interest. For quantitative analysis, establish consistent thresholds for positive staining and employ appropriate software for co-localization analysis.

Validation of multiplex findings is essential. Compare results with serial sections stained with individual antibodies, and confirm key findings with orthogonal methods such as proximity ligation assays or in situ hybridization. This comprehensive approach ensures reliable multiplex immunofluorescence data when studying ELOVL2 in relation to other proteins.

How can researchers distinguish between ELOVL2 and other ELOVL family members in experimental settings?

Distinguishing between ELOVL2 and other ELOVL family members presents a significant challenge due to their structural similarities and partially overlapping functions. The most robust approach combines antibody-based detection with complementary molecular techniques. When selecting antibodies, prioritize those raised against unique regions of ELOVL2 rather than conserved domains shared across the ELOVL family. Examine the immunogen information provided by manufacturers; the ELOVL2 antibody (20308-1-AP) mentioned in the search results was generated using an ELOVL2 fusion protein , which may offer greater specificity.

Western blot analysis can help distinguish between family members based on subtle differences in molecular weight. ELOVL2 has an expected size of approximately 35 kDa , while other family members may migrate slightly differently. Additionally, expression pattern analysis can provide distinguishing information, as ELOVL family members have distinct tissue-specific expression profiles. ELOVL2 is prominently expressed in liver, testis, and retina, whereas other family members show different distribution patterns.

For definitive discrimination, combine antibody-based techniques with nucleic acid-based methods such as qPCR with gene-specific primers or RNA in situ hybridization. These approaches target unique nucleotide sequences and can overcome the limitations of antibody cross-reactivity. Functional assays measuring the elongation of specific fatty acid substrates can further distinguish between ELOVL family members, as each has characteristic substrate preferences.

Finally, genetic approaches using siRNA or CRISPR-mediated knockdown/knockout of specific ELOVL family members, followed by antibody detection, can conclusively demonstrate antibody specificity and distinguish between family members in experimental systems.

What role can ELOVL2 antibodies play in studying the relationship between lipid metabolism and neurodegenerative diseases?

ELOVL2 antibodies offer powerful tools for investigating the increasingly recognized connections between lipid metabolism and neurodegenerative conditions. Methodologically, researchers can employ these antibodies to map ELOVL2 expression patterns across different brain regions in both healthy and pathological states. Using quantitative immunohistochemistry or Western blotting, comparative analysis between control and diseased tissues (such as Alzheimer's or Parkinson's) can reveal alterations in ELOVL2 expression that may contribute to pathogenesis.

Dual-labeling approaches combining ELOVL2 antibodies with markers for specific neural cell types (neurons, astrocytes, microglia, oligodendrocytes) can determine which cells exhibit altered ELOVL2 expression in disease conditions. High-resolution confocal microscopy enables subcellular localization studies to assess whether ELOVL2 trafficking or distribution is disrupted in neurodegenerative diseases. This is particularly relevant as endoplasmic reticulum stress, where ELOVL2 is primarily localized, is a common feature in many neurodegenerative conditions.

For mechanistic investigations, ELOVL2 antibodies can be used in co-immunoprecipitation studies to identify disease-relevant protein interactions. Combined with lipidomic analyses, researchers can correlate ELOVL2 expression levels with changes in polyunsaturated fatty acid profiles in affected brain regions. In experimental models, monitoring ELOVL2 expression changes following therapeutic interventions may identify potential biomarkers of treatment efficacy.

Additionally, laser capture microdissection of specific brain regions followed by Western blotting with ELOVL2 antibodies can provide spatially resolved information about regional vulnerability in neurodegenerative diseases. This multi-faceted approach using ELOVL2 antibodies can significantly advance our understanding of how altered lipid metabolism contributes to neurodegeneration.

How can ELOVL2 antibodies be utilized in aging research and epigenetic clock studies?

ELOVL2 has emerged as one of the most robust epigenetic markers of aging, with its promoter methylation status showing strong correlation with chronological age. ELOVL2 antibodies provide critical tools for exploring the functional consequences of these epigenetic changes at the protein level. Researchers can employ quantitative Western blotting or immunohistochemistry to determine whether DNA methylation changes translate to altered protein expression across different age groups.

A comprehensive methodological approach involves parallel analysis of promoter methylation status (via bisulfite sequencing or pyrosequencing) and protein expression (via antibody-based methods) in the same samples. This correlative analysis can reveal tissue-specific relationships between epigenetic modifications and protein abundance. Multi-label immunofluorescence combining ELOVL2 antibodies with markers of cellular senescence (p16, p21, SA-β-gal) can determine whether cells with altered ELOVL2 expression exhibit senescence phenotypes.

For intervention studies in aging models, ELOVL2 antibodies provide valuable tools for assessing whether treatments that extend lifespan or healthspan (such as caloric restriction or exercise) modulate ELOVL2 expression. Time-course studies across different ages can establish the trajectory of ELOVL2 expression changes and their relationship to functional decline in various tissues. Additionally, chromatin immunoprecipitation experiments can identify transcription factors whose binding at the ELOVL2 promoter changes with age, potentially explaining the observed methylation dynamics.

In human studies, ELOVL2 antibodies enable the analysis of protein expression in biobank samples across diverse age ranges and health conditions. This translational approach can validate findings from experimental models and potentially identify interventional targets to modulate age-related ELOVL2 changes and their downstream consequences.

What considerations are important when using ELOVL2 antibodies for studying tissue-specific differences in fatty acid metabolism?

When investigating tissue-specific differences in fatty acid metabolism using ELOVL2 antibodies, several methodological considerations are essential for obtaining reliable and interpretable results. First, sample preparation protocols must be optimized for each tissue type, as lipid-rich tissues (such as brain or adipose) may require specialized extraction procedures to obtain consistent protein yields and prevent interference from lipids during immunodetection. The inclusion of tissue-specific positive and negative controls is crucial, as ELOVL2 expression varies considerably across tissues, with particularly high expression in liver, testis, and retina.

Antibody validation should be performed independently for each tissue type of interest. The recommended dilution ranges for ELOVL2 antibodies (1:20-1:200 for IHC ) may require tissue-specific optimization. Antigen retrieval conditions may similarly need customization, as tissues differ in fixation properties and protein-protein interactions that can mask epitopes. While TE buffer pH 9.0 is generally recommended , systematic comparison with alternative methods may identify optimal conditions for each tissue type.

When quantifying ELOVL2 expression across different tissues, standardized protocols for image acquisition and analysis are essential. For Western blotting, careful selection of loading controls is necessary, as commonly used housekeeping proteins may show tissue-specific expression variations. For immunohistochemistry, digital image analysis with consistent thresholding criteria enhances quantitative reliability.

To correlate ELOVL2 protein expression with functional outcomes, combine antibody-based detection with lipidomic analyses of the same tissues. This integrative approach can reveal how tissue-specific differences in ELOVL2 expression translate to distinct fatty acid profiles and downstream physiological functions, providing comprehensive insights into the role of ELOVL2 in tissue-specific metabolism.

What storage and handling practices are recommended to maintain ELOVL2 antibody stability and performance?

Proper storage and handling of ELOVL2 antibodies are critical for maintaining their specificity and sensitivity across experiments. According to the search results, ELOVL2 antibodies are typically supplied in PBS with 0.02% sodium azide and 50% glycerol at pH 7.3 . This formulation enhances stability during storage, with the glycerol preventing freezing at -20°C and the sodium azide inhibiting microbial growth. The recommended storage temperature is -20°C, with an expected stability period of one year after shipment when properly stored .

While aliquoting is generally unnecessary for small volume (20μl) antibody preparations stored at -20°C , researchers working with larger volumes should consider creating single-use aliquots to avoid repeated freeze-thaw cycles. Each freeze-thaw cycle can potentially reduce antibody activity by 10-20%, with membrane protein-targeting antibodies like ELOVL2 sometimes showing particular sensitivity to such degradation.

When removing antibodies from storage, allow them to warm gradually to room temperature before opening the container to prevent condensation, which can introduce contaminants and promote antibody degradation. Brief centrifugation before opening is also recommended to collect any solution that may have dispersed during shipping or storage.

How can researchers effectively validate new lots of ELOVL2 antibodies to ensure experimental reproducibility?

Lot-to-lot variation in antibodies represents a significant challenge for experimental reproducibility. When validating new lots of ELOVL2 antibodies, implement a comprehensive validation strategy that compares the new lot directly against a previously validated lot. Begin with Western blot analysis using identical samples and protocols to assess whether the new lot produces the same banding pattern and signal intensity at the expected molecular weight of 35 kDa . Quantitative comparison of signal-to-noise ratios can provide objective measures of performance similarity.

For immunohistochemistry applications, perform parallel staining of serial sections from known positive tissues (such as human testis or hepatocirrhosis tissue ) with both antibody lots. Compare staining intensity, pattern, and background levels using standardized image acquisition settings. Titration experiments with the new lot can determine whether the optimal working dilution matches that of the previous lot or requires adjustment.

Epitope verification is another critical validation step. Review the immunogen information provided by the manufacturer to confirm that the new lot targets the same epitope. For the ELOVL2 antibody mentioned in the search results (20308-1-AP), the immunogen is specified as "ELOVL2 fusion protein Ag14143" . When this information is available, it allows for verification of consistent targeting across lots.

Maintain detailed records of all validation experiments, including images, quantitative analyses, and lot-specific optimizations. This documentation is invaluable for troubleshooting unexpected results and ensuring experimental reproducibility over time. Consider archiving small aliquots of well-performing lots as reference standards for future lot validations.

What are the most significant recent advances in ELOVL2 antibody applications for cutting-edge research?

Recent advances in ELOVL2 antibody applications have expanded their utility across multiple research frontiers. One of the most significant developments has been in aging research, where ELOVL2 antibodies now complement epigenetic studies of the ELOVL2 promoter, which has emerged as one of the most reliable epigenetic clocks. By correlating methylation status with protein expression changes, researchers are gaining deeper insights into the functional consequences of age-related epigenetic modifications.

In neuroscience research, improved co-localization methodologies combining ELOVL2 antibodies with neural cell type-specific markers have advanced our understanding of fatty acid metabolism in the brain. These approaches are revealing cell type-specific vulnerabilities in neurodegenerative conditions and identifying potential metabolic intervention points. The application of high-resolution imaging techniques with ELOVL2 antibodies has enabled more precise subcellular localization studies, clarifying how this enzyme interacts with other components of the lipid synthesis machinery.

Technical advances in multiplex immunofluorescence protocols have facilitated the simultaneous visualization of ELOVL2 with multiple other proteins involved in lipid metabolism pathways. This systems-level approach provides contextual information about how ELOVL2 functions within broader metabolic networks. Additionally, the development of phospho-specific ELOVL2 antibodies (though not mentioned in the search results) represents an emerging area that could reveal regulatory mechanisms controlling ELOVL2 activity through post-translational modifications.

In translational research, the application of ELOVL2 antibodies to patient-derived samples and disease models is bridging basic science with clinical relevance. These studies are identifying potential biomarkers and therapeutic targets in conditions ranging from metabolic disorders to neurodegenerative diseases, highlighting the expanding impact of ELOVL2 research across biomedical fields.

What future directions for ELOVL2 antibody development would most benefit the research community?

Future development of ELOVL2 antibodies should address several unmet needs in the research community. First, the generation of antibodies specifically designed for super-resolution microscopy would significantly advance our understanding of ELOVL2's precise subcellular organization and its dynamic interactions with other endoplasmic reticulum proteins. These specialized antibodies, optimized for techniques such as STORM or PALM, would enable nanoscale mapping of ELOVL2 distribution and potentially reveal functional microdomains within the ER membrane.

The development of phospho-specific and other post-translational modification-specific ELOVL2 antibodies represents another crucial frontier. While current antibodies primarily detect total ELOVL2 protein levels, modification-specific antibodies would reveal regulatory mechanisms controlling ELOVL2 activity. Computational analyses predicting potential phosphorylation, acetylation, or ubiquitination sites could guide the development of these specialized reagents.

Species-specific ELOVL2 antibodies with validated cross-reactivity profiles would benefit comparative biology studies. While current antibodies show reactivity with human, mouse, and rat samples , explicitly validated antibodies for additional model organisms would expand research possibilities. Similarly, antibodies specifically validated for distinguishing between ELOVL2 and other ELOVL family members would address a significant challenge in the field.